|
2023 Conference Publication A phase 2/3, multicenter trial of lenzilumab and azacitidine in chronic myelomonocytic leukemia: The PREACH-M trialHiwase, Devendra, Ross, David, Lane, Steven, Yong, Agnes, Sharplin, Kirsty, Yeung, David, Butler, Lisa, Chappell, Dale, Durrant, Cameron, Hughes, Timothy and Thomas, Daniel (2023). A phase 2/3, multicenter trial of lenzilumab and azacitidine in chronic myelomonocytic leukemia: The PREACH-M trial. 114th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Orlando Fl, Apr 14-19, 2023. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2023-CT085 |
|
2023 Conference Publication Minocycline and/or omega-3 fatty acids added to treatment as usual for individuals with at risk mental states. A large multicenter double blind RCTQurashi, I., Chaudhry, B., Khoso, B. A., Husain, M. O., Hafeez, D., Kiran, T., Lane, S., Naqvi, A. H., Minhas, A. F., Nizami, T. A., Razzaque, B., Bokhari, Q. S., Yung, R. A., Deakin, B. and Husain, N. (2023). Minocycline and/or omega-3 fatty acids added to treatment as usual for individuals with at risk mental states. A large multicenter double blind RCT. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/j.jpsychores.2023.111238 |
|
2023 Conference Publication Immunoproteasome Function Maintains Oncogenic Gene Expression In Kmt2a-complex Driven LeukemiaHeidel, Florian, Tubio-Santamaria, Nuria, Jayavelu, Ashok Kumar, Schnoeder, Tina, Eifert, Theresa, Hsu, Chen-Jen, Perner, Florian, Zhang, Qirui, Wenge, Daniela, Hansen, Fynn, Jyotsana, Nidhi, Lane, Steven, von Eyss, Björn, Deshpande, Aniruddha, Kühn, Michael, Schwaller, Jürg, Ebstein, Frederic, Krüger, Elke, Hochhaus, Andreas, Heuser, Michael, Ori, alessandro, Mann, Matthias and Armstrong, Scott (2023). Immunoproteasome Function Maintains Oncogenic Gene Expression In Kmt2a-complex Driven Leukemia. 2023 Annual Scientific Meeting of the ISEH – International Society for Experimental Hematology, New York, NY United States, 17-20 August 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.exphem.2023.06.049 |
|
2022 Conference Publication Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid LeukemiaBruedigam, Claudia, Porter, Amy H., Song, Axia, Vroeg in de Wei, Gerjanne, Stoll, Thomas, Straube, Jasmin, Cooper, Leanne T., Cheng, Guidan, Kahl, Vivian F.S., Sobinoff, Alexander, Ling, Victoria Y., Jebaraj, Billy Michael Chelliah, Bray, Laura J., Bullinger, Lars, Heidel, Florian H., Kennedy, Glen A., Hill, Michelle M., Pickett, Hilda, Abdel-Wahab, Omar, Hartel, Gunter and Lane, Steven W. (2022). Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-168166 |
|
2022 Conference Publication A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)Gill, Harinder, Palandri, Francesca, Ross, David M., Cochrane, Tara, Tate, Courtney, Lane, Steven W., Larsen, Stephen R., Gerds, Aaron T., Halpern, Anna B., Shortt, Jake, Rossetti, James M., Pettit, Kristen M., Liang, James, Mead, Adam J., Marchetti, Monia, Vannucchi, Alessandro M., Wilson, Andrew J., Goethert, Joachim R., Hanna, Merit, Passamonti, Francesco, Stevenson, William S., Harrison, Claire, Talpaz, Moshe, Vianelli, Nicola and Rienhoff, Hugh Young (2022). A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET). 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans La, Dec 10-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2022-159047 |
|
2022 Conference Publication Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CMLYeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S.M., Shortt, Jake, Burbury, Kate, Viiala, Nicholas, Cunningham, Ilona, Ross, David M., Harrup, Rosemary, Wright, Matthew, Forsyth, Cecily, D'Souza, Alwyn Bernard, Filshie, Robin J., Browett, Peter J., Lane, Steven W., Grove, Carolyn, Grigg, Andrew and Hughes, Timothy (2022). Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-157244 |
|
2022 Conference Publication Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor FractionsSubramanian, Shruthi, Thoms, Julie A., Huang, Yizhou, Jacquelin, Sebastien, Shen, Sylvie, Song, Emma, Joshi, Swapna, Brownlee, Chris, Woll, Petter S., Fajardo, Diego Chacon, Beck, Dominik, Curtis, David J., Yehson, Kenneth, Antonenas, Vicki, O' Brien, Tracey, Trickett, Annette, Powell, Jason, Pitson, Stuart M., Gandhi, Maher K., Cornejo, Paola, Wong, Emily, Lane, Steven W., Gottgens, Bertie, Rokny, Hamid Alinejad, Wong, Jason W. H. and Pimanda, John E. (2022). Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans La, Dec 10-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2022-165620 |
|
2022 Conference Publication Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid LeukemiaEifert, Theresa, Schnoeder, Tina M. M., Hsu, Chen-Jen, Becker, Alicia L., Zhang, Qirui, Mohr, Juliane, Frey, Stephanie, Scholl, Sebastian, Bullinger, Lars, Lane, Steven W. and Heidel, Florian H. (2022). Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans La, Dec 10-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2022-157247 |
|
2021 Conference Publication Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid LeukemiaLing, Victoria Y., Jacquelin, Sebastien, Straube, Jasmin, Haldar, Rohit, Janardhanan, Yashaswini, Cooper, Leanne T., Bruedigam, Claudia, Cooper, Emily, Godfrey, William, Tey, Siok-Keen, Bullinger, Lars, Herold, Marco J., Baell, Jonathan, Bywater, Megan and Lane, Steven W. (2021). Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid Leukemia. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-148379 |
|
2021 Conference Publication A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)Palandri, Francesca, Vianelli, Nicola, Ross, David M., Cochrane, Tara, Lane, Steven W., Larsen, Stephen R., Gerds, Aaron T., Halpern, Anna B., Shortt, Jake, Rossetti, James M., Pettit, Kristen M., Jones, Amber, Peppe, Jennifer, Natsoulis, Georges, Navarro, Willis, Hong, Wan-Jen, Stevenson, William S., Harrison, Claire N., Talpaz, Moshe and Rienhoff, Hugh Young (2021). A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-148210 |
|
2021 Conference Publication A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT<sub>3</sub>-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study)Kipp, David, Loo, Sun, Perkins, Andrew Charles, Lane, Steven W., Blyth, Emily, Ejeti, Anoop Kumar, Bajel, Ashish, Reynolds, John and Wei, Andrew H. (2021). A Phase- Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood-2021-154247 |
|
2021 Conference Publication PREDICTORS OF AND TIME FRAME FOR READMISSION FOLLOWING HOSPITALISATION WITH COMMUNITY ACQUIRED PNEUMONIAChakrabarti, B., Lane, S., Jenks, T., Higgins, J., Kanwar, E., Allen, M. and Wootton, D. G. (2021). PREDICTORS OF AND TIME FRAME FOR READMISSION FOLLOWING HOSPITALISATION WITH COMMUNITY ACQUIRED PNEUMONIA. Winter Meeting of the British-Thoracic-Society (BTS), Electr Network, Feb 17-19, 2021. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/thorax-2020-BTSabstracts.106 |
|
2019 Conference Publication A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 TherapiesAbrams, Simon Timothy, Morton, Ben, Alhamdi, Yasir, Alsabani, Mohmad, Cheng, Zhenxing, Lane, Steven, Welters, Ingeborg, Wang, Guozheng and Toh, Cheng-Hock (2019). A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-128493 |
|
2019 Conference Publication Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-RenewalSchnoeder, Tina M., Schwarzer, Adrian, Perner, Florian, Kirkpatrick, Joanna, Dolnik, Anna, Doehner, Konstanze, Arreba-Tutusaus, Patricia, Assi, Salam A., Bruedigam, Claudia, Kathner, Carolin, Eifert, Theresa, Buschbeck, Marcus, Fedi, Monica Nafria I., Ptasinska, Anetta, Elefanty, Andrew, Ng, Elizabeth, Bierhoff, Holger, Gras, Florian, Matziolis, Georg, Fischer, Klaus-Dieter, Heidenreich, Olaf, Lane, Steven W., Bullinger, Lars, von Eyss, Bjorn, Ori, Alessandro, Bonifer, Constanze and Heidel, Florian H. (2019). Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-Renewal. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-121996 |
|
2018 Conference Publication Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colonVarelias, Antiopi, Bunting, Mark, Ormerod, Kate, Koyama, Motoko, Olver, Stuart, Straube, Jasmin, Kuns, Rachel, Robb, Renee, Henden, Andrea, Cooper, Leanne, Lachner, Nancy, Gartlan, Kate, Lantz, Olivier J., Kjer-Nielsen, Lars, Mak, Jeffrey, Fairlie, David, Clouston, Andrew, McCluskey, James, Rossjohn, Jamie, Lane, Steven, Hugenholtz, Phil and Hill, Geoff (2018). Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon. Immunology 2018™ Meeting, Austin, TX United States, 4-8 May 2018. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.200.supp.55.15 |
|
2016 Conference Publication IL-28 Is a critical cytoprotectant in transplantationHenden, A., Robb, R., Clouston, A., Kuns, R., Lane, S., Gartlan, K. and Hill, G. (2016). IL-28 Is a critical cytoprotectant in transplantation. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016. Weinheim, Germany: Wiley-VCH. |
|
2015 Conference Publication SSB1 AND SSB2 SINGLE-STRANDED DNA BINDING PROTEINS ARE ESSENTIAL FOR HSC FUNCTIONVu, Therese, Shi, Wei, Lane, Steven and Khanna, Kum Kum (2015). SSB1 AND SSB2 SINGLE-STRANDED DNA BINDING PROTEINS ARE ESSENTIAL FOR HSC FUNCTION. 44th Annual Scientific Meeting of the International-Society-for-Experimental-Hematology (ISEH), Kyoto Japan, Sep 17-19, 2015. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.exphem.2015.06.274 |
|
2015 Conference Publication The adaptor protein ASC controls transplantation outcomes independently of the inflammasomeCheong, Melody, Gartlan, Kate, Tey, Siok-Keen, Kuns, Rachel, Lor, Mary, Lineburg, Katie, Tea, Bianca, Shi, Wei, Raju, Jyothy, Zhang, Ping, Varelias, Antiopi, Leveque-El Mouttie, Lucie, Olver, Stuart, Bunting, Mark, Lane, Steven, Boyle, Glen, Ting, Jenny, Schroder, Kate, Engwerda, Christian, Khanna, Kum Kum, Smyth, Mark, MacDonald, Kelli, Koyama, Motoko and Hill, Geoffrey (2015). The adaptor protein ASC controls transplantation outcomes independently of the inflammasome. Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY), New Orleans La, May 08-12, 2015. BETHESDA: AMER ASSOC IMMUNOLOGISTS. |
|
2014 Conference Publication Investigation of mice deficient in matriptase-2, Hfe and transferrin receptor 2 reveals a novel non-hepatic role for Tfr2 in erythropoiesisWallace, D. F., Secondes, E. S., Rishi, G., Ostini, L., Mcdonald, C. J., Lane, S. W., Hooper, J. D., Lopez-Otin, C. and Subramaniam, V. N. (2014). Investigation of mice deficient in matriptase-2, Hfe and transferrin receptor 2 reveals a novel non-hepatic role for Tfr2 in erythropoiesis. Australian Gastroenterology Week 2014, Broadbeach, Australia, 22-24 October 2014. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736_6 |
|
2012 Conference Publication Structure and RNA Recognition in Recombinant STNV CapsidsPhillips, Simon Edward Victor, Lane, Stephen W., Dennis, Caitriona A., Lane, Claire L., Trinh, Chi H., Rizkallah, Pierre J., Bunka, David H., Dykeman, Eric C., Ford, Robert, Barker, Amy, Twarock, Reidun and Stockley, Peter G. (2012). Structure and RNA Recognition in Recombinant STNV Capsids. 56th Annual Meeting of the Biophysical-Society, San Diego Ca, Feb 25-29, 2012. CAMBRIDGE: CELL PRESS. |
